Vardi J R, Tadros G H, Malhotra C, Charney T, Shebes M, Foemmel R
Department of Obstetrics and Gynecology, Maimonides Medical Center, Brooklyn, New York 11219.
Surg Gynecol Obstet. 1989 Apr;168(4):296-301.
Plasma lipid associated sialic acid (LASA-P) was evaluated in relation to disease status and disease progression in a total of 52 consecutive patients with advanced carcinoma of the ovaries (FIGO stage III and IV). Forty-three individuals with benign gynecologic diseases served as controls. There were three groups. Group 1 included 23 untreated patients who had LASA-P values above normal before debulking operations. Group 2 consisted of 12 patients who completed 12 courses of chemotherapy after debulking operations and presented with negative findings at second look operation (SLO). LASA-P levels were measured in these patients prior to SLO. Eight of 12 patients had normal LASA-P values for a specificity rate of 67 per cent. Four patients had elevated values with no clinical evidence of disease. Group 3 had 17 patients who failed to respond to cytotoxic chemotherapy after initial debulking procedures. All patients in this group had persistent or recurrent disease that was documented at re-exploration or at SLO. Elevated LASA-P levels were noted in 14 of 17 patients for a sensitivity rate of 82 per cent. Rising LASA-P values in serial samples were the only signs of disease recurrence in three of five patients who completed 12 courses of chemotherapy and in whom SLO showed surgical evidence of disease. The predictive value for positive and negative results for all patients were 92.2 and 72.7 per cent, respectively. In spite of the relatively low sensitivity and specificity rates in groups 2 and 3, LASA-P can be used successfully as a valuable adjunct to monitor the course of the disease during treatment in patients with advanced carcinoma of the ovaries.
对52例连续的晚期卵巢癌患者（国际妇产科联盟分期III和IV期）的血浆脂质相关唾液酸（LASA-P）与疾病状态和疾病进展进行了评估。43例患有良性妇科疾病的个体作为对照。分为三组。第1组包括23例未治疗的患者，这些患者在肿瘤细胞减灭术前LASA-P值高于正常。第2组由12例患者组成，他们在肿瘤细胞减灭术后完成了12个疗程的化疗，二次探查手术（SLO）结果为阴性。在这些患者进行SLO之前测量LASA-P水平。12例患者中有8例LASA-P值正常，特异性率为67%。4例患者值升高，但无疾病的临床证据。第3组有17例患者在初始肿瘤细胞减灭术后对细胞毒性化疗无反应。该组所有患者均有持续性或复发性疾病，在再次探查或SLO时得到证实。17例患者中有14例LASA-P水平升高，敏感性率为82%。在完成12个疗程化疗且SLO显示有疾病手术证据的5例患者中，有3例患者系列样本中LASA-P值升高是疾病复发的唯一迹象。所有患者阳性和阴性结果的预测值分别为92.2%和72.7%。尽管第2组和第3组的敏感性和特异性率相对较低，但LASA-P可成功用作监测晚期卵巢癌患者治疗期间疾病进程的有价值辅助手段。
